HDAC6 and prostate carcinoma: In this study, we established LASSBio-1911, a potent HDAC6/8 inhibitor, and LASSBio-2208, a potent dual PI3K/HDAC6 inhibitor, as two novel therapeutic potential drugs against prostate cancer with high metastatic potential and limited treatment options.